Abstract
Loss of vision in Behçet’s disease is one of the most common, as well as one of the most serious, of its varied manifestations. Total blindness may often be the eventual outcome. The underlying problem in the eye, as well as in other organ systems, is an occlusive vasculitis. Although the most common ocular symptom is that of iridocyclitis, the presence of retinovascular lesions, especially necrotizing retinitis, is well known but often obscured by the severity of the anterior reaction, which precludes a good view of the retina. While Behçet’s disease is characterized by spontaneous remissions and relapses, no external factors have been found to explain the length of remissions. Blindness, which occurs in up to 25% of patients, is one of the major causes of permanent disability.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atmaca LS: Fundus change associated with Behcet’s disease. Graefes Arch Clin Exp Ophthalmol 227: 340–344,1989
Barra C, Beifort R, Abreu M: Behcet’s disease in Brazil: a review of 49 cases with emphasis on Ophthalmie manifestation. Jpn J Ophthalmol 35: 339–346,1991
Benezra D, Cohen E: Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 70: 589–592,1986
Benezra D, Cohen E, Chajek T: Evaluation of conventional therapy versus cyclosporin A in Behcet’s Syndrome. Transplant Proc 20 (suppl 4): 136–143,1988
Choi YS, Chung H: Clinical manifestation and visual prognosis in Behçet’s disease. J Korean Ophthalmol Soc 36: 1514–1521,1995
Durand JM, Soubeyrand J: Interferon-alpha 2B for refractory ocular Behçet’s disease [letter]. Lancet 344: 333,1994
Fenton RM, Easom HA: Behcet’s Syndrome: a histopathologic study of the eye. Arch Ophthalmol 72: 71–81,1964
Foster CS, Baer JC, Raizman MB: Therapeutic responses to systemic immunosuppressive chemotherapy in patients with Behcet’s Syndrome affecting the eyes. In O’Duffy JD, Kokman E, eds. Behcet’s disease: basic and clinical aspects. New York, Marcel Dekker, 581–588,1991
Kang SJ, Kim HB: Behcet’s disease in Korean. J Korean Ophthalmol Soc 33: 332–341,1992
Kim HB, Kim EK, Park K, Chung H: Results of Cyclosporin A therapy in Behcet’s disease. J Korean Ophthalmol Soc 31: 469–475,1990
Mamo JG: The rate of visual loss in Behcet’s disease. Arch Ophthalmol 84: 451–452,1970
Michelson JB, Chisari FV: Behcet’s disease. Surv Ophthalmol 26: 190–203,1982
Mishima S, Masuda K, Izawa Y, Mochizuki M: Behcet’s disease in Japan: Ophthalmologic aspects. Trans Am Ophthalmol Soc 77: 225–233,1979
Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K: Effectiveness of cyclosporine therapy for Behcet’s disease. Arthritis Rheum 28: 671–679,1985
Oshima Y, Shimizu T, Yokohari R: Clinical studies on Behcet’s Syndrome. Ann Rheum Dis 22: 36–45,1963
Palestine AG, Austin HA III, Balow JE, Antonovuck TT, Sabnis SG, Preus HG, Nussenblatt RB: Renal histopathologic aherations in patients treated with Cyclosporine for Uveitis. N Engl J Med 314: 1293–1298,1986
Raizman MB, Foster CS: Plasma exchange in the therapy of Behcet’s disease. Graefes Arch Clin Exp Ophthalmol 227: 360–363,1989
Yazici H, Pazarh H, Barnes CG: A controlled trial of azathioprine in Behcet’s Syndrome. N Engl J Med 322: 281–285, 1990
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kim, H.B. (2001). Ophthalmologic Manifestation of Behçet’s Disease. In: Behçet’s Disease. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56455-0_20
Download citation
DOI: https://doi.org/10.1007/978-3-642-56455-0_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-63094-1
Online ISBN: 978-3-642-56455-0
eBook Packages: Springer Book Archive